Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Phase II data and leadership exit – Cardiff shares halve in two days

February 02, 2026

Cardiff Oncology reported positive Phase II data for onvansertib in RAS-mutated metastatic colorectal cancer while simultaneously announcing the departures of its CEO and CFO. The twin disclosures...

Thermo Fisher shutters Mass. site: layoffs exceed 100

February 02, 2026

Thermo Fisher Scientific filed notice that it will close its Franklin, Massachusetts facility and lay off more than 100 employees, according to a state filing. The company attributed the move to...

AbbVie bets on precision immunology: reverse translation to guide combos

February 02, 2026

In a perspective piece, Kori Wallace, AbbVie’s VP of Clinical Development for Immunology, outlines a strategic shift toward precision immunology built on reverse translation and rational...

Lentiviral vectors take center stage in next‑gen gene therapies

February 02, 2026

A recent study reviewed advances in lentiviral-vector technology that are reshaping gene-therapy delivery, highlighting improvements in tropism, payload capacity, and safety profiling. Authors...

In vivo CARs move closer to clinic – new reagents and protocols emerge

February 02, 2026

Researchers outlined progress in in vivo CAR therapeutic development, describing delivery strategies (viral vectors, nanoparticles), CRISPR editing needs, and assay frameworks for assessing CAR...

Brown uncovers molecular switch to sensitize glioblastoma to therapy

February 02, 2026

Brown University scientists published a Cell Reports study that decodes a molecular mechanism limiting glioblastoma response to existing therapies and identifies a targetable pathway to enhance...

FDA Halts Regenxbio Trials: Cancer Case Prompts Clinical Hold

February 02, 2026

The FDA placed clinical holds on two Regenxbio gene therapy studies after a participant in one study developed cancer, raising fresh safety and regulatory questions for viral-vector programs....

EU Overhauls Rules: Generics and Biosimilars Could Come Sooner

February 02, 2026

European regulators will implement new laws that tighten the pathways companies use to delay generic and biosimilar competition, forcing drugmakers to navigate additional regulatory steps to...

Thermo Fisher Shutters Mass. Site: 100+ Employees Affected

February 02, 2026

Thermo Fisher Scientific announced the closure of its Franklin, Massachusetts facility, triggering layoffs for more than 100 employees according to a state notice. The company cited site...

Neoadjuvant FOLFIRINOX–Nivolumab: Pilot Phase 1 Yields Promising Signals in PDAC

February 02, 2026

A pilot phase 1 trial evaluated neoadjuvant modified FOLFIRINOX combined with nivolumab in pancreatic ductal adenocarcinoma (PDAC) and reported encouraging safety and preliminary activity,...

Brown Identifies Pathway to Sensitize Glioblastoma to Therapy

February 02, 2026

Researchers at Brown University disclosed a molecular mechanism that could enhance therapeutic responses in glioblastoma, offering a potential pathway to overcome intratumoral resistance, the team...

Intranasal H5N1 Vaccine Prevents Infection in Rodents — WashU Study

February 02, 2026

Washington University researchers developed an intranasal adenoviral-vectored H5N1 vaccine that protected mice and hamsters from highly pathogenic avian influenza in preclinical testing, the team...

University of Ottawa Launches OMARI: Medical AI Hub Established

February 02, 2026

The University of Ottawa inaugurated the Ottawa Medical Artificial Intelligence Research Institute (OMARI) to centralize medical-AI research, led by Dr. Khaled El Emam, Canada Research Chair in...

Machine Learning Tool Maps Scope of Paper-Mill Fraud in Cancer Science

February 02, 2026

Researchers at Queensland developed a machine‑learning tool that identifies suspicious publications and mapped a broad spread of likely paper‑mill outputs affecting cancer research literature. The...

C‑Suite Shakeup and Data Release Send Cardiff Stock Down 45%

February 02, 2026

Cardiff Oncology reported positive Phase II signals for onvansertib in RAS‑mutated metastatic colorectal cancer while simultaneously announcing the resignations of CEO Mark Erlander and CFO James...

In vivo CARs: New Reagent Suites Target Translation Bottlenecks

February 02, 2026

An industry-focused review outlined practical steps to advance in vivo CAR approaches from concept to clinical translation and highlighted commercial reagent solutions aimed at de‑risking the...

FDA halts Regenxbio trials: cancer case triggers clinical holds

February 02, 2026

The FDA placed clinical holds on two Regenxbio gene‑therapy studies after a participant developed cancer, raising fresh safety questions for adeno‑associated virus (AAV) and related viral vector...

Thermo Fisher shutters Franklin lab — more than 100 layoffs

February 02, 2026

Thermo Fisher Scientific announced the closure of its Franklin, Massachusetts facility and notified state regulators of workforce reductions affecting over 100 employees. The company filed a...

Cardiff leadership exit: shares plunge after Phase II update

February 02, 2026

Cardiff Oncology disclosed positive Phase II data for onvansertib in RAS‑mutated metastatic colorectal cancer at the same time its CEO and CFO resigned, prompting a sharp market reaction and a...

Nasal H5N1 vaccine prevents infection in rodents: WashU reports

February 02, 2026

Washington University School of Medicine reported an intranasal adenoviral‑vectored H5N1 vaccine that protected hamsters and mice from highly pathogenic avian influenza strains and remained...